Fig. 5From: Clinical status of patients 1 year after hospital discharge following recovery from COVID-19: a prospective cohort studySARS-CoV-2 RBD-specific antibody levels in recovery patients with COVID-19. A Levels of anti-RBD IgA, IgG, and IgM antibodies in 163 recovery patients at acute phase and 1-year follow-up. The difference was determined by the paired samples Wilcoxon test. B Levels of anti-RBD IgA, IgG, and IgM between 173 non-severe patients and 49 severe patients at 1-year follow-up. The difference between two groups was determined by the Wilcoxon test. COI, cut-off Index. ns, P > 0.05; **, P ≤ 0.01; ***, P ≤ 0.001Back to article page